Part-Time
Global cannabis cultivation, processing, and retail
No salary listed
New Hope, PA, USA
In Person
See people who can refer or advise you
TerrAscend operates globally in the cannabis sector, covering cultivation, processing, manufacturing, and retail. It grows cannabis plants, turns them into products such as dried flowers, oils, edibles, and other infused goods, and sells these through its own retail brands and distribution channels. The company also provides ancillary services to support the cannabis industry. What makes TerrAscend different is its integrated, multi-country footprint and strategy of strategic acquisitions (including Arise Bioscience, The Apothecarium, State Flower, and Ilera Healthcare) to expand its brands and market presence, while maintaining strong standards for quality and regulatory compliance grounded in scientific research. Its goal is to continue growing its market position by expanding its product range, geographic reach, and capabilities through innovation, rigorous quality control, and acquisitions, serving medical patients, recreational users, and other cannabis industry businesses.
Company Size
201-500
Company Stage
IPO
Headquarters
Ontario, California
Founded
2017
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Unlimited Paid Time Off
401(k) Retirement Plan
401(k) Company Match
Employee Assistance Program
Paid Parental Leave
Short & Long Term Disability
Flexible Spending Account
Wellness Program
Employee Discount
Paid Vacation
IRS pushes back on cannabis tax refunds as rescheduling reshapes 280E fight. MSOs are still hoping their tax gambit pays off. Reading Time: 3 mins read The Internal Revenue Service (IRS) is pushing back against multi-state operators, just as they have grown more bold when it comes to writing off cannabis-related business expenses in the wake of last spring's rescheduling of medical cannabis. A little more than two years ago, a few multi-state operators grabbed headlines with their claims that they figured out legal loopholes around article 280E of the U.S. tax code, which forbids companies from writing off expenses when the business is involved with a Schedule I or II drug. These loopholes would allow companies to recoup hundreds of thousands, if not millions of dollars in lost revenue from the IRS. Since then, the IRS has started filing cases in attempts to claw back erroneous cannabis-related tax returns, which was further complicated when acting Attorney General Todd Blanche officially announced medical cannabis would be moved to Schedule III, making it exempt from 280E. "The Attorney General's announcement made clear that state licensed medical cannabis sales are no longer subject to 280E taxes," said George Archos during Verano's (VERNOF) April 30 quarterly earnings call. "With almost 60% of our retail revenue derived from medical cannabis sales in the first quarter, we are in a position to immediately benefit from the medical rescheduling ruling from a tax perspective which we are actively evaluating as more information and guidance from the Treasury Department and IRS becomes available." Verano was just one of several companies that seem to be banking on tax savings in the wake of the rescheduling announcement. A rough accounting of potential tax savings if 280E did not apply to the top multi-state operators (MSO), would reach a reported $1.6 billion. Curaleaf (CURLF) has about $96.5 million in uncertain tax liabilities related to the enforcement of 280E, according to the company's interim financial report from May 5, 2026. "The Company has adopted a tax position, supported by legal interpretations, asserting that the restrictions of Section 280E do not apply to its cannabis operations," said the 59-page filing. "While the Company believes the Section 280E Position is supported by sound legal interpretations, the cannabis industry operates in a complex and evolving regulatory environment." TerrAscend (TSNDF) and Ascend Wellness (AAWH) both filed quarterly earnings reports for the first quarter of 2024 that included announcements the companies submitted revised tax returns for prior years in order to claim business expenses. At the time, neither company was explicitly about their respective legal strategies supporting their claims. TerrAscend expects up to $26 million in tax returns for their amended claims, while Ascend Wellness did not disclose how much they expect back. The previous month, Trulieve announced it received $112 Million in tax refunds after resubmitted claims. The IRS attempts to claw back cannabis tax returns Despite the increasingly bullish approach MSOs appear to have toward writing off business expenses, the federal government has begun challenging those attempts in court. The IRS sued TerrAscend on May 18, 2026, seeking repayment of tax returns that it claims were erroneously paid. Prior to that, the IRS filed what is likely the first lawsuit attempting to claw back cannabis tax returns that were prohibited under 280E, when the government filed suit against New Mexico Top Organics at the end of 2024. Recently in the New Mexico Top Organics case, the IRS argued on March 6, 2026, that federal courts up to that point have been consistent in how the law regards cannabis, particular in terms of the U.S. tax case. "Despite many taxpayer challenges, federal courts have consistently held that section 280E is constitutionally valid and have created a robust legal authority supporting its validity and applicability to sellers of marijuana," said the IRS in a 45-page seriatim answering brief before the U.S Tax Court. About six weeks later, on April 22, the federal government moved medical cannabis to Schedule III, meaning 280E no longer applied. The proposed rule was published in the Federal Register on April 28. New Mexico Top Organics answered the IRS's argument on May 18, with a 27-page response. "The rescheduling order reflects an understanding that medical marijuana has fit within the meaning of Schedule III (rather than Schedule I) for a long time," said the response. The case remains pending, just as the federal rescheduling process continues. Hearings pertaining to the scheduling of adult-use cannabis are expected to last as late as July 15.
TerrAscend, a North American cannabis operator, has completed an oversubscribed private placement of senior secured convertible debentures, raising $21.7 million. The company used $11.1 million to retire higher-rate senior unsecured convertible debt, with remaining proceeds allocated for mergers and acquisitions. The debentures mature on 30 September 2031, carry an 8% interest rate, and are convertible into common shares at $0.87 — a 25% premium to the 20-day volume-weighted average price. The notes are secured by a second lien on the company's US business. Executive Chairman Jason Wild stated the financing reduces blended interest costs and extends debt maturity, providing flexibility for accretive acquisitions to expand retail operations in existing high-growth markets. An insider participated in the placement, purchasing 1,000 debentures for $1 million.
TerrAscend, a North American cannabis operator, announced preliminary unaudited first quarter 2026 results, reporting net revenue of $65.5 million, up from $64.3 million in the same quarter last year. Gross profit margin reached 52.8%, whilst general and administrative expenses remained flat quarter-over-quarter. The company generated positive cashflow from operations for the fifteenth consecutive quarter. Executive chairman Jason Wild attributed the performance to improved operational momentum and recent medical cannabis rescheduling developments. TerrAscend operates in Pennsylvania, New Jersey, Maryland, Ohio and California, with retail operations in Canada. The company will host an earnings conference call on 7 May 2026 to discuss detailed results. Results exclude Michigan operations, which are reported as discontinued operations from the second quarter of 2025.
Mike Tyson and TerrAscend expand TYSON 2.0 footprint into Pennsylvania and Maryland. TORONTO, March 31, 2026 (GLOBE NEWSWIRE) - TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis operator, today announced the official launch of TYSON 2.0 products in Pennsylvania and Maryland. This expansion marks the latest milestone in TerrAscend's exclusive partnership with the legendary heavyweight champion's premier cannabis brand. The Knockout Lineup The initial rollout features a curated selection of premium flower and high-potency vapes, available through TerrAscend's Apothecarium dispensaries and third-party wholesale partners: * Pennsylvania: Launching with 3.5g and 28g premium flower jars alongside live resin disposable vapes. * Maryland: Debuting with 3.5g and 14g flower SKUs and distillate vapes, with a wider variety of product formats slated for release throughout 2026. Executive Commentary "Bringing the TYSON 2.0 experience to Pennsylvania and Maryland is something I have been wanting to do for some time," said Mike Tyson, co-founder of the brand. "This brand is a reflection of my personal journey with cannabis, and partnering with TerrAscend allows us to ensure every consumer and patient gets the quality and intensity they deserve." Jason Wild, Executive Chairman of TerrAscend, noted the significance of the expansion: "Mike brings an unmatched level of energy and focus to the industry. Following our success in other markets, we are proud to leverage our cultivation and retail footprint to bring this iconic brand to patients and consumers across PA and MD." Availability TYSON 2.0 products are now in stock at all Apothecarium locations and select partner dispensaries across both states. About TerrAscend TerrAscend is a leading TSX-listed cannabis company with interests across the North American cannabis sector, including operations in Pennsylvania, New Jersey, Maryland, Ohio, and California through TerrAscend Growth Corp. and retail operations in Canada. TerrAscend operates The Apothecarium and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. TerrAscend's cultivation and manufacturing practices yield consistent, high-quality cannabis, providing industry-leading product selection to both the medical and legal adult-use markets. The Company owns or licenses several synergistic businesses and brands including The Apothecarium, Cookies, Lemonnade, Ilera Healthcare, Kind Tree, Legend, State Flower, Wana, and Valhalla Confections. For more information visit www.terrascend.com. Caution Regarding Cannabis Operations in the United States Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the U.S. Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis in the United States. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation. While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve TerrAscend of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against TerrAscend. The enforcement of federal laws in the United States is a significant risk to the business of TerrAscend and any proceedings brought against TerrAscend thereunder may adversely affect TerrAscend's operations and financial performance. Forward-Looking Information This press release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe," "intend", "plan", "forecast", "project", "estimate", "look forward to", "outlook" and other similar expressions, and include, but are not limited to, statements with respect to the Company's expectation of future availability of funds under the uncommitted term loan; and the Company's growth prospects in new and existing markets. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, current and future market conditions; risks related to federal, state, provincial, territorial, local and foreign government laws, rules and regulations, including federal and state laws in the United States relating to cannabis operations in the United States; and the risk factors set out in the Company's most recently filed MD&A, filed with the Canadian securities regulators and available under the Company's profile on SEDAR+ at www.sedarplus.ca and in the section titled "Risk Factors" in the Company's Annual Report for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 6, 2025. The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether, as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws. Released March 31, 2026
TerrAscend stock: navigating the evolving cannabis landscape for North American investors. 30.03.2026 - 19:22:34 | ad-hoc-news.de TerrAscend Corp. (ISIN: CA88160R1087) operates as a leading cannabis cultivator and retailer with a strong footprint in key North American markets. Investors eye its growth potential amid regulatory shifts and market consolidation. This analysis explores what drives the stock today and key factors to monitor. TerrAscend Corp. stands as a prominent player in the North American cannabis industry, focusing on cultivation, processing, and retail distribution. Listed under ISIN CA88160R1087 on the Canadian Securities Exchange as TSND, the company targets vertically integrated operations to capture value across the supply chain. For North American investors, TerrAscend represents exposure to the burgeoning legal cannabis market, where evolving regulations and consumer trends shape long-term opportunities. As of: 30.03.2026 By Elena Voss, Senior Financial Editor at NorthStar Market Insights: TerrAscend embodies the resilience of cannabis operators adapting to regulatory maturation in North America. Company overview and business model. Official source All current information on TerrAscend directly from the company's official website. TerrAscend Corp. maintains a vertically integrated business model that spans cultivation, manufacturing, distribution, and retail. This structure allows the company to control quality from seed to sale, a critical advantage in a fragmented industry. Operations center on high-quality flower production and branded products like cookies and concentrates, appealing to recreational and medical consumers alike. The company's portfolio includes state-of-the-art cultivation facilities designed for efficiency and scalability. By focusing on premium genetics and sustainable practices, TerrAscend differentiates itself from commodity producers. Retail banners such as Apothecarium provide direct-to-consumer channels, enhancing brand loyalty and margins. Geographically, TerrAscend holds licenses in multiple U.S. states including New Jersey, Pennsylvania, and California, alongside Canadian operations. This multi-jurisdictional presence mitigates regional risks while positioning the company for national expansion as barriers lower. Investors value this footprint for its potential to capitalize on population density and market maturity. Market position and competitive landscape. Sentiment and reactions In the competitive cannabis sector, TerrAscend competes with multi-state operators (MSOs) like Curaleaf and Green Thumb Industries. Its edge lies in operational efficiency and a focus on East Coast markets, where adult-use legalization drives demand. The company's wholesale distribution strengthens ties with third-party retailers, expanding reach without heavy capital outlay. Market share gains depend on execution in high-growth states. Pennsylvania and New Jersey represent significant opportunities due to large populations and recent regulatory openings. TerrAscend's ability to secure additional licenses or partnerships will define its trajectory against larger peers. Branding plays a pivotal role, with in-house lines gaining traction among discerning consumers. As the industry shifts from price wars to premiumization, TerrAscend's product innovation supports sustained revenue growth. North American investors monitor these dynamics for signs of margin expansion. Sector drivers and regulatory environment. The cannabis sector benefits from ongoing legalization trends across North America. In the U.S., over 24 states have recreational markets, with more under consideration. Canada, post-2018 legalization, sees maturing recreational sales alongside medical stability. TerrAscend navigates a complex regulatory landscape, including state-specific compliance and federal restrictions. Potential U.S. rescheduling of cannabis to Schedule III could unlock banking access and tax relief, benefiting operators like TerrAscend. Investors watch federal progress closely for industry-wide catalysts. Supply chain constraints and potency caps influence production strategies. TerrAscend adapts by optimizing yields and diversifying formats like edibles and vapes. Broader economic factors, such as inflation and consumer spending, also impact discretionary purchases like cannabis. Financial strategy and growth catalysts. TerrAscend pursues a disciplined financial strategy emphasizing cash flow generation and debt reduction. Investments in automation enhance cultivation efficiency, lowering costs per gram. Retail expansion through acquisitions or organic growth bolsters recurring revenue. Key catalysts include license approvals and market share capture in new jurisdictions. Vertical integration minimizes intermediary costs, supporting profitability as wholesale prices stabilize. The company's balance sheet strength allows flexibility for opportunistic moves. For growth-oriented investors, TerrAscend offers leverage to sector tailwinds without excessive dilution risks. Management's track record in integrations signals capability to execute amid consolidation waves sweeping the industry. Investor relevance for North americans. Further developments, updates, and context on the stock can be explored quickly through the linked overview pages. North American investors find TerrAscend appealing due to its U.S.-centric operations, offering indirect exposure to domestic legalization without direct state-level investments. Canadian listing provides liquidity and transparency via SEDAR filings. Currency dynamics between CAD and USD add a layer for U.S. holders. The stock aligns with portfolios seeking high-beta growth in emerging markets. Dividend policies remain secondary to reinvestment, suiting long-term holders. ETF inclusions could boost visibility and trading volume. Performance benchmarks against the MOC index highlight relative strength during sector recoveries. Investors assess TerrAscend for its role in diversified cannabis allocations. Risks and open questions. Regulatory delays pose the primary risk, with federal reform timelines uncertain. State-level enforcement variations could disrupt operations. Intense competition pressures pricing power, especially in oversupplied markets. Execution risks in scaling retail and cultivation persist. Economic downturns may curb consumer spending on non-essentials. Investors should watch cash burn rates and debt covenants closely. Open questions include acquisition pipelines and international ambitions. Path to positive free cash flow remains pivotal. Dilution from financings could impact per-share value if markets weaken. Supply disruptions from weather or input costs add volatility. Black market persistence challenges legal sales growth. North American investors prioritize management's navigation of these hurdles. Disclaimer: Not investment advice. Stocks are volatile financial instruments. Trojaner, Phishing, Datenklau: So schützen Android-Experten ihre eigenen Geräte. Gratis-Sicherheitspaket vom 03. April: Jeden Tag werden 560.000 neue Schad-Apps für Android entdeckt - viele tarnen sich als harmlose Downloads. Die IT-Experten von Computerwissen haben ihre bewährtesten Schutzmaßnahmen in einem kostenlosen Paket zusammengestellt: 5 konkrete Anleitungen, die jeder Android-Nutzer in unter 10 Minuten umsetzen kann. Ohne technische Vorkenntnisse. Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen - dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren. Für. Immer. Kostenlos. CA88160R1087 | TERRASCEND | boerse | 69031577 | bgmi